Trends in the Management and Outcomes of Neuroendocrine… : Annals of Surgery
armamentarium has evolved over recent decades but there remains uncertainty regarding optimal treatment selection and sequencing. Methods: Retrospective cohort study pooling data from 4 specialist centres of excellence in the United Kingdom and Germany for individuals diagnosed with neuroendocrine liver metastases between 1st Jan 1990 and 31st December 2020. We explored trends in theranostic strategies over three decades and quantified overall survival (cohort, and by decade-defined temporal periods). Results: We identified 551 individuals with NE LM with a median age at diagnosis of 59.1 years; 453 (82.2%) had synchronous metastases, and 402 (73.0%) underwent multimodal therapy. In all centres somatostatin receptor-based PET/CT and MRI were the preferred imaging techniques. There were significant trends in the use of somatostatin analogues and peptide receptor radionuclide therapy but the number of surgical resections remained stable. Overall survival (OS) at 5- and 10-years was 77.5%
